My research centers on deciphering the pathogenesis of immunological disorders and developing novel immune therapeutics. Autoimmune diseases, cancer immunotherapy, and vaccines are current topics of interests. The central theme of my research is aimed to provide useful solutions for unmet medical needs. The inhibitory receptors, e.g. FcγRIIB on B cells and myeloid cells and PD-1 on T cells, are my long-term research interests. We investigate the fundamental aspects of immunology, e.g. germinal center reaction, as well as the molecular mechanisms of immune dysfunction, e.g. immune exhaustion. To better address these questions, we not only used the existing animal models but also generated our own genetically modified mice for in-depth translational and preclinical studies. In addition, the antibody drug development and delivery methods and antibody engineering are in progress for development of target therapy for autoimmune diseases and cancers. In addition, we extend our research projects to other important diseases and unsolved problems, e.g. emerging infectious diseases, and neurodegenerative diseases.

近期代表著作：

1] The lupus-associated FcγRIIB-I232T polymorphism results in impairment in the negative selection of low-affinity germinal center B cells via c-Abl. Arthritis Rheum. 2018.

2] B-cell ELISpot assay to quantify antigen-specific antibody-secreting cells in human peripheral mononuclear cells. In the 3rd edition of Handbook of ELISPOT (2018) in Springer/Humana Press book series “Methods in Molecular Biology”.

3] Dual immuno-renal targeting of 7-benzylidenenaltrexone alleviates lupus nephritis via FcγRIIB and HO-1. J Mol Med (Berl). 2018;96:413-25. [Abstract]

4] Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus. Exp Mol Med. 2017;49:e381. [Abstract]

5] The Isolation, differentiation, and quantification of human antibody-secreting B cells from blood: ELISpot as a functional readout of humoral immunity. J Vis Exp. 2016;118. doi: 10.3791/54582. [Abstract]

6] FcγRIIB mediates antigen-independent inhibition on human B lymphocytes through Btk and p38 MAPK. J Biomed Sci. 2015;22(1):87-98. [Abstract]

7] Live cell imaging reveals that the inhibitory FcγRIIB destabilizes B-cell receptor membrane-lipid interactions and blocks immune synapse formation. J. Immunol, 180:793-9. 2008.  [Abstract]

1] Inhibitory Fc receptor and other inhibitory immune receptors

2] Mechanism and application of inhibitory receptors in autoimmunity, tumor immunity, neuroinflammation and vaccination

3] Antibody gene cloning and antibody engineering, e.g. anti-influenza antibody

4] Development of antibody-based as well as cell-based immunotherapeutics

1] Nucleofector II

2] MACSmix homogenizer